Skip to Main Content

Paper Details

Deployment of convalescent plasma for the prevention and treatment of COVID-19.
J Clin Invest
542
2020
COVID, COVID-19, MERS, Middle East respiratory syndrome, SARS, SARS-1, SARS-CoV, SARS-CoV-2, Severe acute respiratory syndrome coronavirus, convalescent plasma, coronavirus 2, coronavirus disease, coronaviruses, health crisis, infectious diseases, patient
Author NameAffiliation
Evan M Bloch
Shmuel Shoham
Arturo CasadevallBloomberg School of Public Health, Johns Hopkins University
Arturo CasadevallBloomberg School of Public Health, Johns Hopkins University
Bruce S Sachais
Beth H Shaz
Jeffrey L WintersMayo Clinic
Camille M van BuskirkMayo Clinic
Brenda J GrossmanWashington University School of Medicine in St. Louis
Michael J JoynerMayo Clinic
Andrew PekoszBloomberg School of Public Health, Johns Hopkins University
Bryan LauBloomberg School of Public Health, Johns Hopkins University
Louis M Katz
Nigel Paneth
Nigel PanethMichigan State University
Nigel Paneth
Nigel PanethMichigan State University
Eric A Gehrie
Steven L SpitalnikColumbia University Irving Medical Center, New York-Presbyterian Hospital
Eldad A HodColumbia University Irving Medical Center, New York-Presbyterian Hospital
Liise-Anne PirofskiAlbert Einstein College of Medicine and Montefiore Medical Center
Aaron A R Tobian
  • 1 - 22

Datasets

Release 1.2